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Abstract 
miR-34a is a transcriptional target of p53, and implicated in carcinogenesis. We 
studied the role of miR-34a methylation in a panel of hematological malignancies 
including acute leukemia (AML, ALL), chronic leukemia (CLL and CML), multiple 
myeloma (MM) and non-Hodgkin's lymphoma (NHL). The methylation status of 
miR-34a promoter was studied in 12 cell lines and 188 diagnostic samples by 
methylation-specific PCR. miR-34a promoter was unmethylated in normal controls 
but methylated in 75% lymphoma and 37% myeloma cell lines. Hypomethylating 
treatment led to re-expression of pri-miR-34a transcript in lymphoma cells with 
homozygous miR-34a methylation. In primary samples at diagnosis, miR-34a 
methylation was detected in 4% CLL, 5.5% MM samples, and 18.8% of NHL at 
diagnosis but none of ALL, AML and CML (p=0.011). In MM patients with paired 
samples, miR-34a methylation status remained unchanged at progression. Amongst 
lymphoid malignancies, miR-34a was preferentially methylated in NHL (p=0.018), in 
particular natural killer/T cell (NK/T cell) lymphoma. In conclusion, amongst 
hematological malignancies, miR-34a methylation is preferentially hypermethylated 
in NHL, in particular NK/T cell lymphoma, in a tumor-specific manner, therefore the 
role of miR-34a in lymphomagenesis warrants further study.
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Introduction 
 DNA methylation involves the addition of a methyl group to the number 5 carbon 
of the cytosine ring in the CpG dinucleotide, by catalyzing the cytosine into 
methylcytosine through DNA methyltransferase.1,2 Cancer cells are characterized by 
global DNA hypomethylation but gene-specific hypermethylation of 
promoter-associated CpG islands of tumor suppressor genes (TSGs), resulting in 
transcriptional repression, and hence serve as an alternative mechanism of gene 
inactivation. Based on a pathway-specific approach, multiple TSGs across pathways 
including cell cycle regulation, JAK/STAT signaling, WNT signaling, and DAP 
kinase-associated intrinsic tumor suppression have been shown to be inactivated by 
gene hypermethylation in leukemia, lymphoma and multiple myeloma.3-11 
 MicroRNA (miRNA or miR) is a single-stranded, non-coding RNA molecule of 
22-25 nucleotides, which leads to downregulation of target protein expression.12 
miRNAs are involved in carcinogenesis. miRNAs can be either oncogenic (oncomir) 
when TSGs are targeted, or tumor suppressive (tumor suppressive miRNAs) when 
oncogenes are targeted.12 Little is known about the role of hypermethylation of tumor 
suppressor miRNAs in haemic cancers. 
p53 is an important tumor suppressor gene inactivated in the majority of cancers. 
However, inactivation of p53 in haemic cancers is relatively uncommon, and present 
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in only about 10%-20% of cases.13 On the other hand, miR-34a, localized to 1p36, is a 
transcriptional target of p53, mediating cellular apoptosis. It was shown to be 
hypermethylated in breast, colon and lung cancers, and downregulate CDK6 
translation by binding on the 3’ untranslated region (3’ UTR) of the CDK6 mRNA, 
thereby demonstrating the tumor suppressor role of miR-34a.14 Therefore, we 
postulated that while genetic inactivation of p53 is uncommon in hematological 
malignancies, epigenetic inactivation of miR-34a, a direct transcriptional target of p53, 
may occur in hematological cancers. 
In this study, we aimed to study the role of miR-34a methylation in a wide range 
of hematological malignancies including acute myeloid leukemia (AML), chronic 
myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic 
leukemia (CLL), multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). 
Materials and methods 
Patient samples 
Diagnostic bone marrow or tissue samples were obtained in 20 ALL, 20 AML, 
11 CML in chronic phase, 50 CLL, 55 MM and 32 NHL patients. Diagnosis of 
leukemia and lymphoma were made according to the FAB Classification and WHO 
Classification of Tumors respectively.15-18 Patient demographics were listed in Tables 
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1 and 2. The study has been approved by IRB of Queen Mary Hospital with informed 
consent. 
Methylation-specific polymerase chain reaction (MSP) 
DNA was extracted from bone marrow samples of ALL, AML, CML, CLL and MM 
at diagnosis, diagnostic tissues (either lymph node or nasal biopsy in nasal NK-cell 
lymphoma) in patients with NHL, lymphoma cell lines (SU-DHL-1 (ALK+), 
SUP-M2 (ALK+), SUP-T1, and KARPAS-299 (ALK+)), and myeloma cell lines 
(KMS-12-PE, LP-1, MOLP-8, NCI-H929, OPM-2, RPMI-8226, U-266, and WL-2) 
by standard method. MSP for aberrant gene promoter methylation was performed as 
previously described.3,8 Treatment of DNA with bisulphite for conversion of 
unmethylated cytosine to uracil (but unaffecting methylated cytosine) was performed 
with a commercially available kit (EpiTect Bisulphite Kit, Qiagen, Germany). Primers 
used for the methylated MSP (M-MSP) and unmethylated MSP (U-MSP) are shown 
in supplementary Table. MSP primers for miR-34a promoter was designed within a 
region of established promoter activity upstream the characterized complete sequence 
of primary miR-34a transcript.19,20 DNA from normal bone marrow donors (N=5) was 
used as negative control, while enzymatically methylated control DNA (CpGenome 
Universal Methylated DNA, Chemicon) was used as positive control in all the 
experiments. MSP was performed in a thermal cycler (9700, Applied Biosystems, 
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Foster City, CA, USA) with the following cycling conditions: 95oC for 5 minutes, 35 
cycles of 95oC for 30 seconds, specific annealing temperature for 30 seconds 
(supplementary Table), 72oC for 30 seconds, and a final extension of 10 minutes at 
72oC. The MSP mixture contained 50 ng of bisulphite-treated DNA, 0.2 mM dNTPs, 
2 mM MgCl2, 10 pmol of each primer, 1 X PCR buffer, and 2.5 units of AmpliTaq 
Gold DNA Polymerase (ABI, Foster City, CA, USA) in a final volume of 50 μl. Ten 
microliters of PCR products were loaded onto 6% non-denaturing polyacrylamide 
gels, electrophoresed, and visualized under ultraviolet light after staining with 
ethidium bromide. 
Cell lines and culture 
LP-1 and RPMI-8226 were kind gifts from Dr Orlowski (Department of 
Hematology/Oncology, MD Anderson Cancer Center, USA). WL-2 was kindly 
provided by Dr Andrew Zannettino (Myeloma and Mesenchymal Research 
Laboratory, Division of Haematology, Institute of Medical and Veterinary Science, 
Adelaide, Australia). Other lymphoma (SU-DHL-1, SUP-M2, SUP-T1, and 
KARPAS-299) and multiple myeloma (KMS-12-PE, MOLP-8, OPM-2, and U-266) 
cell lines were purchased from Deutsche Sammlung von Mikroorganismen und 
Zellkulturen (DMSZ) (Braunschweig, Germany). NCI-H929 was purchased from 
American Type Culture Collection (ATCC). Cell cultures were maintained in RPMI 
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media 1640 (Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum 
(Invitrogen, Carlsbad, CA), 50 U/ml penicillin, and 50 μg/ml streptomycin 
(Invitrogen, Carlsbad, CA) in a humidified atmosphere of 5% CO2 at 37oC. 
Hypomethylating treatment of cell lines with homozygous miR-34a methylation 
Lymphoma (KARPAS-299) cells were seeded in six-well plates at a density of 
1x106 cells/ml, and cultured with 0.5-1 μM of 5-Aza-2’-deoxycytidine (5-AzadC) 
(Sigma-Aldrich, St. Louis, MO, USA) for 3 days. Cells on day 0 and day 3 of cell 
treatment were harvested. 
RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was isolated and reverse transcribed using mirVanaTM miRNA 
Isolation Kit (Ambion, Austin, TX, USA) and SuperScriptTM First-Strand Synthesis 
System for RT-PCR (Invitrogen, Carlsbad, CA, USA) respectively, according to the 
manufacturers’ instructions. RT-PCR primers for the pri-miR-34a and p53 transcript, 
and PCR conditions were summarized in supplementary Table. 
Statistical analysis 
Correlation between miR-34a methylation status with type of haemic 
malignancy was computed by the Chi-square test (or Fisher Exact test). All p-values 
were two-sided. 
Results 
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MSP 
Controls. Sequencing of the M-MSP products from the positive control showed the 
expected nucleotide changes after bisulphite treatment, therefore confirming complete 
bisulphite conversion and specificity of MSP (Figure 1A). None of the five normal 
control marrows showed aberrant methylation of miR-34a (Figure 1B). The positive 
and negative controls showed the expected MSP results (normal DNA: U-MSP 
positive / M-MSP negative; methylated DNA: U-MSP negative / M-MSP positive). 
Lymphoma cell lines. The profile of methylation of miR-34a in lymphoma cell lines 
was shown in Figure 1C. SUP-T1 and KARPAS-299 (ALK+) were homozygously 
methylated for miR-34a; whereas SU-DHL-1 (ALK+) was hemizygously methylated 
for miR-34a; and only SUP-M2 (ALK+) was completely unmethylated for miR-34a. 
Myeloma cell lines. The profile of methylation of miR-34a in myeloma cell lines was 
shown in Figure 1D. KMS-12-PE, OPM-2, and WL-2 were homozygously methylated 
for miR-34a; whereas LP-1, MOLP-8, NCI-H929, RPMI-8226, and U-266 were 
completely unmethylated for miR-34a. 
Primary samples. miR-34a was hypermethylated in none of CML, ALL and AML in 
addition to 2 (4%) CLL, 3 (5.5%) MM and 6 (18.8%) NHL samples. (Figure 2) 
Amongst the lymphoid malignancies, there was significantly more frequent miR-34a 
methylation in NHL than MM, CLL or ALL (p=0.027). In lymphoma samples, 
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miR-34a was more frequently methylated in NK/T cell (N=4; 44.4%) than B-cell 
(N=2; 16.7%) or PTCL, NOS (N=0) (p=0.039). (Table 2) In the 12 MM patients with 
bone marrow samples at both diagnosis and progression including two with miR-34a 
methylation at diagnosis, the methylation status of miR-34a did not change at disease 
progression (data not shown). 
5-AzadC treatment of KARPAS-299 cells  
Untreated KARPAS-299 cells were completely methylated for miR-34a. Upon 
5-AzadC demethylation treatment, miR-34a U-MSP signal emerged on day 3 (Figure 
3A), with re-expression of pri-miR-34a as shown by semi-quantitative RT-PCR 
(Figure 3B). p53, the transcriptional activator of pri-miR-34a, was constitutively 
expressed before and after 5-AzadC treatment. (Figure 3B) 
Discussion 
Methylation studies require precise identification of gene promoter region and 
CpG island for proper MSP primer design. The complete sequence of primary 
miR-34a transcript has previously been described by other groups using rapid 
amplification of cDNA ends (RACE),19,20 and published to GenBank (accession: 
EF592573).19 The promoter region and transcription start site (TSS) of miR-34a is 
therefore mapped to > 30 kb upstream of mature miR-34a. The promoter activity of 
which under the control of p53, the transcriptional activator of miR-34a, has been 
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confirmed by luciferase reporter assay.19 CpG island has been found in the above 
region. Hence, our MSP primer sets designed for this study were selected according to 
the above region, where > 30 kb upstream of mature miR-34a, with TSS, p53 binding 
site, proven promoter activity, and CpG island. 
In this study, there are several interesting observations. First, we showed that 
miR-34a is not methylated in normal blood cells but is hypermethylated in myeloma 
and lymphoma cell lines, and hence it is tumor-specific and consistent with its tumor 
suppressor role.19 By contrast, miRs such as miR-127 and miR-373 are 
hypermethylated in both normal and tumor cells, which will hence represent 
tissue-specific but not tumor-specific miR methylation.21 Moreover, in KARPAS-299 
cells, miR-34a hypermethylation was associated with gene silencing, which was 
reversed by hypomethylating treatment.  
Secondly, in primary samples, miR-34a was preferentially methylated in 
lymphoma samples, in particular, extranodal NK/T cell lymphoma, nasal type. 
NK-cell lymphoma is an Epstein-Barr virus–associated, aggressive extranodal 
lymphoma more frequently encountered in Asia, and Central and South America.22 
Various tumor suppressor genes have been shown to be frequently hypermethylated in 
NK-cell lymphoma including p73, CDKN2A, CDKN2B, hMLH1 and RARβ,23 but 
hypermethylation of miR-34a is likely the first report of methylation of miR in 
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NK-cell lymphoma. On the other hand, miR-34a methylation is infrequent in other 
hematological malignancies, in contrast to solid cancer such as prostatic carcinoma, in 
which miR-34a methylation was detected in 79% of primary solid cancer samples.14 
Thirdly, p53 is an important independent prognostic factor in CLL, with a much 
inferior survival in patients with p53 inactivation by either del(17p) or p53 mutation.24 
However, unlike solid cancers, in which p53 inactivation may occur in up to 60% of 
cases,25 del(17p) and p53 mutation only occur in ≤10% of CLL patients at diagnosis. 
However, other components of the p53-associated tumor suppression pathways have 
been shown to be inactivated by mutation or hypermethylation. For example, ATM, 
involved in the ATM-CHK2-P53 pathway, is inactivated by del(11q23) in about 20% 
of patients is another adverse prognostic factor for survival.26 Moreover, 
death-associated protein kinase (DAPK), involved in the 
DAPK/p14/HDM2/p53/Apaf-1 apoptosis pathway, has been shown to be frequently 
hypermethylated in CLL.27 Furthermore, recently, miR-34b and miR-34c, with similar 
function to miR-34a, has been shown to be hypermethylated in colon cancer.28 These 
will be another interesting target of methylation to study. 
In addition to hypermethylated promoter, miR-34a is localized to 1p36, which is 
frequent for loss of heterozygosity (LOH) in different kinds of cancers. LOH serves as 
one of the mechanisms for TSG inactivation in fulfilling the Kundson’s two-hit 
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hypothesis.29 Loss of 1p heterozygosity is common in solid cancers such as breast, 
colon, lung, and neuroblastoma.30-31 In hematological cancers, loss of 1p36 
heterozygosity and the associated tumor suppressor genes is also common.32-34 In 
particular, high frequency of promoter hypermethylation for p73 or LOH of p73 at 
1p36 was found in NHL patients.34 Hence, miR-34a inactivation might potentially 
result from promoter hypermethylation together with LOH at 1p36 in the samples, 
thereby fulfilling the Kundson’s two-hit hypothesis for TSG inactivation. 
In summary, amongst hematological malignancies, miR-34a is preferentially 
hypermethylated in NHL, in particular NK-cell lymphoma, in a tumor-specific 
manner. miR-34a methylation is associated with reversible gene silencing, and the 
role of miR-34a in lymphomagenesis warrants further study. 
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Legend 
Figure 1. Methylation of miR-34a. (A) Schematic diagram showing the locations of 
p53 binding site (solid green box), and distribution of CpG dinucleotides (solid 
vertical lines) over transcription start site (TSS) of pri-miR-34a and precursor 
miR-34a (solid black box). Sequence analysis of the M-MSP product from 
bisulphite-treated positive control DNA showed that the cytosine [C] residues of CpG 
dinucleotides were methylated and remained unchanged, whereas all the other C 
residues were unmethylated and were converted to thymidine [T], confirming 
complete bisulphate conversion and specificity of MSP. (B) U-MSP showed that the 
methylated control [P] was totally methylated, and all five normal controls [N1-N5] 
were unmethylated. In the M-MSP, the methylated control was methylated but all 
normal controls were unmethylated. (C) For the lymphoma cell lines, SUP-T1 and 
KARPAS-299 were completely methylated for miR-34a. (D) For the myeloma cell 
lines, KMS-12-PE, OPM-2, and WL-2 were completely methylated for miR-34a; 
whereas LP-1, MOLP-8, NCI-H929, RPMI-8226, and U-266 were completely 
unmethylated for miR-34a. 
Figure 2. Methylation of miR-34a in primary samples (B: reagent blank; S: primary 
sample; N: normal control; P: positive control with methylated DNA). 
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Figure 3. Effect of 5-Aza-2’-deoxycytidine (5-AzadC) treatment on KARPAS-299 
lymphoma cells. (A) M-/U-MSP analysis of miR-34a promoter methylation status (P: 
positive control; N: normal bone marrow; D0: day 0; D3: day 3; B: reagent blank). (B) 
semi-quantitative RT-PCR analysis of the p53 status and pri-miR-34a expression 
(MW: marker; B: reagent blank; D0: day 0; D3: day 3; NoRT: negative control 
without reverse transcriptase). Sequencing analysis of the semi-quantitative RT-PCR 
products for the detection of p53 and pri-miR-34a expression was shown in the upper 
panel. 5-AzadC treatment resulted in progressive demethylation of miR-34a promoter, 
and re-expression of the pri-miR-34a in KARPAS-299 cells. 
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Figure 4. Chromatin 
Immunoprecipitation (ChIP) assay of 
KMS-12-PE myeloma cells with 
5-Aza-2’-deoxycytidine (5-AzadC) 
with or without valproic acid (VPA). 
A) Schematic diagram showing the 
locations of the ChIP primer sets (R1 
and R2) used, p53 binding site (solid 
green box), and the distribution of 
CpG dinucleotides (solid vertical 
lines) over the transcription start site 
(TSS) of pri-miR-34a and the mature 
miR-34a (solid black box). B) 
Chromatin DNA was 
... [4]
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Table 1. Patient demographics 
Type   
CLL (N=50)  
   Gender (male/female) 40/10 
   Age (years)  
      median 65.5 years 
      range 37-91 years 
   Rai stage  
      ≤ 2 23 (46%) 
      >2 27 (54%) 
   Lymphocyte count (range; median) 10-236 x 109/L (median: 17) 
MM (N=55)  
   Gender (male/female) 35/20 
   Age (years)  
      median 57 years 
      range 25-87 years 
   Durie Salmon stage (I/II/III)  
      I 10 (18.2%) 
      II 14 (25.5%) 
      III 31 (56.4%) 
   Ig type  
      G 32 (58.2%) 
      A 13 (23.6%) 
      LC 10 (18.2%) 
  
AML (N=20) N=20 
   Gender (M/F) 9/11 
   Age (years)  
      median 41.5 
      range 20-72 
   FAB type  
      M1/M2/M4/M5 3/14/2/1 
ALL (N=20) N=20 
   Gender (M/F) 11/9 
   Age (years)  
      median 35 
      range 13-62 
   MIC type  
      C/PB/EPB/T 6/10/1/3 
CML (N=11)  
   Chronic phase 11 
   Gender (M/F) 7/4 
   Age (years)  
      median 41 
      range 22-87 
G: IgG type; A: IgA type; LC: light chain myeloma; M1: FAB M1; M2: FAB M2; M4: FAB M4; M5: FAB 
M5; MIC: morphologic-immunophenotypic-classification; C: common ALL; PB: precursor B ALL; EBP: 
early B precursor; T: pre-T ALL 
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Table 2. Non-Hodgkin’s lymphoma patient demographics and miR-34a methylation result 
 
Lineage Type N M : F Age (years) 
range 
(median) 
Nodal/extranodal miR-34 
methylated 
miR-34a 
unmethylated 
Mature T AITL 4 3 : 1 56-74 (68) all nodal 0 4 
 ALCL 1 1 : 0 49 (49) Nodal  0 1 
 PTCL, 
NOS 
6 5 : 1 48-75 (68) 3 nodal/3 extranodal 
(muscle/tonsil/maxillary 
mass) 
0 6 
 NK/T 9 5 : 4 48-74 (68) 3 nasal, 6 extranasal (3 
soft tissue; 2 LN; 1 
NK-cell leukemia)  
4 5 
Mature B FL 8 6 : 2 50-77 (64) all nodal 1 7 
 MCL 2 2 : 0 56-77  Both nodal + BM 0 2 
 NMZL 2 1 : 1 56-73 (64) Both nodal + BM 1 1 
        
AITL: angioimmunoblastic T-cell lymphoma; ALCL: anaplastic large-cell lymphoma; PTCL: peripheral T-cell lymphoma, not otherwise specified; FL: follicular lymphoma;  
MCL: mantle cell lymphoma; NMZL: Nodal marginal zone lymphoma; NK: Extranodal NK/T-cell lymphoma (nasal or extranasal type); BM: bone marrow; LN: lymph node 
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ChIP-PCR. Chromatin immunoprecipitation (ChIP) assays were carried out 
following the manufacturer’s manual (Upstate Biotechnology, Cat# 17-610). Briefly, 
2x106 cells were used per ChIP. Cells were treated with 1% formaldehyde for 10 min. 
After washing by cold PBS, cells were resuspended in lysis buffer and sonicated on ice 
using 431A cup horn (Misonix, Farmingdale, NY, USA). Chromatin was sheared into 
fragments ranging between 200 and 800 bp in size. After removing 1% as ‘Input’, 
immunoprecipitation was performed by adding anti-H3K4me3 (Upstate, Cat# 04-745), 
anti-H3K9me3 (Upstate, 17-625), anti-H3K9ac (Upstate, 17-658), anti-H3K27me3 
(Upstate, 17-622) and normal rabbit IgG respectively and incubating at 4°C overnight. To 
collect the immunoprecipitated complexes, magnetic protein A beads were added. After 
washing, the beads were treated with proteinase K and crosslinks were reversed by 
heating. Then DNA was extracted and used in confirmation PCR with the oligonucleotide 
primers that were picked from GAPDH promoter22 and Alu repeats.23 (supplementary 
Table) For mir-34a, two sets of ChIP-PCR primers (supplementary Table) embedded in 
the promoter-associated CpG island were used, one is 540 bp upstream of miR-34a 
transcription start site (TSS), and the other overlap the p53 binding site which is 
downstream of miR-34a TSS.24 (Figure 4) The PCR products were visualized by 6% 
polyacrylamide gel electrophoresis and the assays were done in duplicate. 
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5-AzadC and VPA treatment of KMS-12-PE cells  
Untreated KMS-12-PE cells were completely methylated for miR-34a. Upon 5-AzadC 
demethylation treatment, miR-34a U-MSP signal emerged on day 3. (Figure 3A) 
However, pri-miR-34a transcript was not reexpressed by 5-AzadC alone or a combination 
of 5-AzadC and VPA. (Figure 3B) NCI-H929, which was unmethylated for miR-34a with 
constitutive expression of pri-miR-34a, served as positive control for pri-miR-34a 
expression. p53, constitutively expressed in NCI-H929, was also expressed in KMS cells 
both before and after treatment of 5-AzadC +/- VPA. (Figure 3B) Moreover, PCR on 
DNA fragment pulled down from chromatin immunoprecipitation (i.e. ChIP-PCR) in 
untreated KMS-12-PE cells showed relative abundance of trimethyl H3K9 and trimethyl 
H3K27 in Alu repeat element and the homozygously methylated miR-34a promoter but 
not GAPDH promoter. (Figure 4B, rows 1-3) Upon 5-AzadC treatment, high level of 
trimethyl H3K9 and trimethyl H3K27 persisted in addition to persistent absence of 
trimethyl H3K4 and acetylated H3K9 at the miR-34a promoter. (Figure 4B, row 4) 
Treatment of KMS-12-PE cells with a combination of 5-AzadC and VPA led to 
appearance of trimethyl H3K4 together with a low level of acetylated H3K9. (Figure 4B, 
row 5) Similar histone modification was observed by the use of ChIP-PCR primers 
amplifying over the p53 binding site. (Figure 4B, rows 6-8) 
Primary samples. miR-34a was hypermethylated in none of CML, ALL and AML in 
addition to 2 (4%) CLL, 3 (5.5%) MM and 6 (18.8%) NHL samples. (Figure 5) Amongst 
the lymphoid malignancies, there was significantly more frequent miR-34a methylation 
in NHL than MM, CLL or ALL (p=0.027). In lymphoma samples, miR-34a was more 
frequently methylated in NK (N=4; 44.4%) than B-cell (N=2; 16.7%) or PTCL, NOS 
(N=0) (p=0.039). (Table 1) In the 12 MM patients with bone marrow samples at both 
diagnosis and progression including two with miR-34a methylation at diagnosis, the 
methylation status of miR-34a did not change at disease progression (data not shown). 
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Similarly, in the myeloma line KMS-12-PE, homozygous miR-34a methylation was 
associated with gene silencing. However, hypomethylating treatment of KMS-12-PE 
cells did not result in miR-34a reexpression despite successful demethylation. Therefore, 
the histone profile at the miR-34a promoter was studied to see if failure of miR 
reexpression was due to unsuccessful modification of histone code. ChIP study of 
KMS-PE-12 cells showed that, as expected, a euchromatin histone code (i.e. trimethyl 
H3K4 and acetyl H3K9) was associated with GAPDH promoter, and a silencing 
heterochromatin histone code (i.e. trimethyl H3K9 and trimethyl H3K27) with the Alu 
repeat elements, which is normally hypermethylated.12 Therefore, in addition to the 
technical controls evidenced by the positive amplification in the input DNA, and absence 
of amplification in the IgG control, GAPDH and Alu repeats served as biological controls 
for open and closed chromatin configurations. However, despite restoring 
transcription-ready, open histone code at the miR-34a promoter in KMS-12-PE cells, i.e. 
emergence of trimethyl H3K4 and acetyl H3K9, upon treatment of cells with a 
combination of 5-AzadC and VPA, miR-34a expression was still not demonstrated. This 
might be explained by the fact that p53, and hence its transcriptional target, miR-34a, is 
inducible upon DNA damage, successful demethylation may render a transcription-ready 
state but miR-34a reexpression would require presence of p53, and hence additional 
trigger of DNA damage.26 However, RT-PCR for p53 showed that p53 transcript was 
indeed present, and hence absence of p53 could not account for non-expression of 
miR-34a. Another possibility was that the histone code as revealed by ChIP-PCR did not 
match the chromatin configuration at the transcription start site (TSS) as the TSS of the 
primary miR-34a was localised at >30Kb upstream of the mature miR-34a. (Figure 4A) 
However, our ChIP-PCR primer was indeed selected from the miR-34a TSS DNA 
sequence, and hence represented an accurate histone status at the TSS. On the other hand, 
the R1 region is more than 500bp upstream of miR-34a TSS, whereas the p53 binding site 
was about 230 base pairs downstream of miR-34a TSS. To ensure restoration of a similar 
euchromatin status at both the p53 binding site and miR-34a TSS, we designed another 
set of ChIP-PCR primers at the p53 binding site, which also showed emergence of 
trimethyl H3K4 and acetyl H3K9 data after hypomethylating therapy. Therefore, 
non-expression of miR-34a could not be acccounted by a discordant chromatin 
configuration at the p53 binding site and the miR-34a TSS. Finally, in this ChIP study, 
sustained high levels of trimethyl H3K9 and H3K27 was demonstrated despite successful 
promoter DNA demethylation. The persistence of this heterochromatin histone code has 
also been reported in colorectal cancer cells SW480, in which trimethyl H3K9 and 
trimetyl H3K27 persisted or even increased, when the hypermethylated soluble Wnt 
inhibitors SFRP2 and SFRP5 were successfully demethylated and reexpressed upon 
hypomethylation treatment.27 Therefore, it appeared that the emergence of trimethyl 
H3K4 and possibly acetyl H3K9 accounts for the miR reexpression, and persistent H3K9 
and H3K27 trimethylation does not impede gene reexpression.  
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Figure 3. Treatment of KMS-12-PE myeloma cells with 5-Aza-2’-deoxycytidine 
(5-AzadC) with or without valproic acid (VPA). (A) M-/U-MSP analysis of miR-34a 
promoter methylation status. 5-AzadC treatment resulted in progressive demethylation of 
miR-34a promoter in KMS-12-PE cells. (B) Semi-quantitative RT-PCR analysis of the 
p53 and pri-miR-34a expression. No expression of the pri-miR-34a transcript upon 
5-AzadC alone or combined 5-AzadC + VPA treatment in KMS-12-PE cells. NCI-H929 
myeloma cell line, which was completely unmethylated for miR-34a and expressed 
pri-miR-34a was used as positive control. RT-PCR of GAPDH served as an internal 
control (B: reagent blank; NoRT, negative control without reverse transcriptase). 
Figure 4. Chromatin Immunoprecipitation (ChIP) assay of KMS-12-PE myeloma cells 
with 5-Aza-2’-deoxycytidine (5-AzadC) with or without valproic acid (VPA). A) 
Schematic diagram showing the locations of the ChIP primer sets (R1 and R2) used, p53 
binding site (solid green box), and the distribution of CpG dinucleotides (solid vertical 
lines) over the transcription start site (TSS) of pri-miR-34a and the mature miR-34a (solid 
black box). B) Chromatin DNA was immunoprecipitated with antibodies for trimethyl 
H3K4, trimethyl H3K9, acetyl H3K9, trimethyl H3K27 and normal rabbit IgG. PCR 
amplification of the GAPDH promoter region, Alu repetitive sequence and miR-34a 
promoter in chromatin immunoprecipitated DNA fragments. In untreated KMS-12-PE 
cells, there was a high level of trimethyl H3K4 and modest amount of acetyl H3K9 but 
absence of trimethyl H3K9 at GAPDH promoter. (first row) Conversely, there was a high 
level of trimethyl H3K27 and modest amount of trimethyl H3K9, but absence of 
trimethyl H3K4 and acetyl H3K9 at the Alu repeat sequence (second row) and miR-34a 
promoter (third row). After 5-AzadC treatment, there was persistently high level of 
trimethyl H3K9, trimethyl H3K27, and absence of trimethyl H3K4 and acetyl H3K9, at 
the miR-34a promoter. (fourth row) However, combined treatment with 5-AzadC and 
VPA led to appearance of a substantial level of trimethyl H3K4 and a modest amount of 
acetyl H3K9. (fifth row) Histone modification status observed was consistent between 
ChIP primer sets designed prior the TSS of pri-miR-34a and over the p53 binding site. 
(sixth to eighth rows) 
Figure 5. Methylation of miR-34a in primary samples (B: reagent blank; S: primary 
sample; N: normal control; P: positive control with methylated DNA). 
 
 
